Thomas Joseph Russo Net Worth

Thomas Joseph Russo biography

Thomas Joseph Joseph Russo serves as Chief Financial Officer of the Company. Prior to joining us, Mr. Russo was the Vice President, Head of Commercial Finance of Gilead from July 2016 until October 2019. From October 2014 through June 2016, Mr. Russo was Gilead’s Senior Director–Commercial Operations Finance Center of Excellence, and from October 2012 until September 2014, Mr. Russo held other positions of increasing responsibility at Gilead, including Senior Director– HCV Commercial Operations and Senior Director–Commercial Planning. From 2004 through September 2012, Mr. Russo was an Equity Research Analyst–Biotechnology at Robert W. Baird & Co., Inc., where he advised institutional investors on biotechnology stocks. Mr. Russo holds a B.S. in Biological Sciences from the University of Notre Dame and an M.B.A. from The University of Chicago Booth School of Business. Mr. Russo is also a CFA charterholder.

What is the salary of Thomas Russo?

As the Chief Financial Officer of Assembly Biosciences Inc, the total compensation of Thomas Russo at Assembly Biosciences Inc is $2,131,450. There are 2 executives at Assembly Biosciences Inc getting paid more, with John McHutchison having the highest compensation of $7,007,210.

How old is Thomas Russo?

Thomas Russo is 48, he's been the Chief Financial Officer of Assembly Biosciences Inc since 2019. There are 15 older and 3 younger executives at Assembly Biosciences Inc. The oldest executive at Assembly Biosciences Inc is Alan Lewis, 74, who is the Independent Director.

What's Thomas Russo's mailing address?

Thomas's mailing address filed with the SEC is C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD., FOURTH FLOOR, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Assembly Biosciences Inc

Over the last 10 years, insiders at Assembly Biosciences Inc have traded over $1,523,622 worth of Assembly Biosciences Inc stock and bought 1,245,980 units worth $1,060,065 . The most active insiders traders include Sciences, Inc. Gilead, Myron Z Holubiak y Helen Susan Kim. On average, Assembly Biosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $389,399. The most recent stock trade was executed by Nicole S White on 2 August 2024, trading 785 units of ASMB stock currently worth $11,171.

What does Assembly Biosciences Inc do?

assembly biosciences, inc. (nasdaq: asmb) is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and novel oral live biotherapeutics for disorders associated with the microbiome. assembly is developing two innovative platform programs: an hbv program advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. assembly’s hbv program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic hbv. the company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current good manufacturing practices and a patent-pending delivery system, gemicel®, which allows for targeted ora

Assembly Biosciences Inc executives and stock owners

Assembly Biosciences Inc executives and other stock owners filed with the SEC include:

• John McHutchison,
  President, Chief Executive Officer, Director
• Jacqueline Papkoff,
  Senior Vice President, Chief Scientific Officer Microbiome
• Thomas Joseph Russo,
  Chief Financial Officer
• Luisa Stamm,
  Chief Medical Officer
• Dr. John G. McHutchison A.O., FRACP, M.D.,
  CEO, Pres & Director
• Jason A. Okazaki,
  Chief Operating Officer
• Dr. William E. Delaney IV, Ph.D.,
  Chief Scientific Officer
• William Ringo,
  Non-Executive Independent Chairman of the Board
• Myron Holubiak,
  Independent Director
• Alan Lewis,
  Independent Director
• Anthony Altig,
  Independent Director
• Susan Mahony,
  Independent Director
• Richard DiMarchi,
  Independent Director
• Helen Kim,
  Independent Director
• Nicole White,
  Senior Vice President - Pharmaceutical Development and Manufacturing
• Gina Consylman,
  Independent Director
• Jason Okazaki,
  Chief Legal and Business Officer
• William Delaney,
  Chief Scientific Officer - Virology
• Steven Knox,
  Senior Vice President - Clinical Development
• David Houck,
  Senior Vice President - Product Development and Portfolio Management
• Michele Anderson,
  Chief Devel. Officer
• Dr. Tharaknath Rao,
  Head of Microbiome Clinical Devel. & Sr. VP
• Dr. Richard J. Colonno,
  Sr. Advisor
• Jennifer A. Troia MHROD, SHRM-SCP, SPHR,
  Chief HR Officer
• Lauren Glaser,
  Sr. VP of Investor Relations & Corp. Affairs
• Michael P. Samar,
  CFO & Principal Accounting Officer
• Dr. Adam Zlotnick,
  Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board
• Dr. Uri A. Lopatin M.D.,
  Co-Founder and Clinical & Scientific Advisor
• Graham K Cooper,
  See Remarks
• Mark Auerbach,
  Director
• David Jonathan Barrett,
  See Remarks
• Thomas E Rollins,
  Chief Development Officer
• Uri A Lopatin,
  Chief Medical Officer
• Michael Houghton,
  
• Derek A Small,
  Director
• Richard James Colonno,
  EVP & CSO, Virology Ops
• Capital Fund Qualified, L.P...,
  10% owner
• Lisa Johnson Pratt,
  
• Anuj Gaggar,
  Chief Medical Officer
• Adam Zlotnick,
  10% owner
• Sciences, Inc. Gilead,
  10% owner
• Michael P. Samar,
  Chief Financial Officer
• Jeanette M Bjorkquist,
  Principal Accounting Officer
• Alexander Schornstein,
  10% owner